Bristol-Myers Squibb will acquire Celgene in blockbuster $74B deal

(By Adam Feurerstein and Matthew Herper for STAT)

In a blockbuster deal between two of biopharma’s largest players, Bristol-Myers Squibb said Thursday it plans to buy Celgene for $74 billion.  Continue reading article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.